Cobra Biologics and Alligator Bioscience extend drug development partnership
Project will deliver second cell line to manufacture immuno-oncology antibody ADC-1015 following ADC-1013 success
Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB (Alligator), a Swedish biotechnology company.
Alligator has requested further support from the team at Cobra to develop the cell line to produce a new drug candidate, ADC-1015, a bispecific immune activator developed to induce superior immune activation.
Cobra is using its expression system, maxXpress, along with a historically documented master cell bank (CHO-S) and chemically defined media. This delivers a time-saving cell line development and clone selection process suitable for GMP manufacture.
In May 2015, Cobra released details of its involvement in manufacturing immuno-oncology antibody ADC-1013, as part of Alligator’s Phase 1 trial in advanced solid tumours. Earlier this month, as a result of the company’s exceptional achievements within the life science industry, Alligator won the coveted SwedenBIO Award 2016.
Peter Coleman, CEO Cobra Biologics, commented: ‘Cobra has been manufacturing protein therapeutics since 1995 and our maximum protein expression platform, maxXpress, has proven to be very popular to customers looking for both speed and quality. I am delighted that Cobra has the opportunity to continue working with Alligator on their promising clinical programmes and would like to congratulate the team on their prestigious SwedenBIO Award.’
Dr Per Norlén, CEO, Alligator Bioscience, commented: ‘Alligator has a longstanding and successful collaboration with Cobra and has seen very good results using their maxXpress system. We are very happy to continue the collaboration with Cobra on our ADC-1015 drug development programme.’